The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)

Sponsor
Institut de Recherche pour le Developpement (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05951751
Collaborator
Centre Muraz (Other), Medical Research Council (Other), Institut Pasteur (Industry), REVS PLUS Burkina Faso (Other), Young Gambian Mums Fund (Other), National AIDS Control Program Gambia (Other)
2,800
1
20

Study Details

Study Description

Brief Summary

The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 4 in The Gambia.

The TRI-MOM program has two components:
  1. an "intervention" component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT.

  2. an "evaluation" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.

Condition or Disease Intervention/Treatment Phase
  • Other: TRI-MOM intervention
N/A

Detailed Description

The TRI-MOM (TRIple elimination Model Of Mother-to-child transmission of HIV/Syphilis and HBV in Burkina Faso and The Gambia) program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV MTCT in nine maternal and child health services, 5 in Burkina Faso and 4 in The Gambia. In The Gambia, the program will be conducted in collaboration with the national HIV, sexually transmitted infections (STI) and hepatitis programmes.

The TRI-MOM program has two components:
  1. an "intervention" component consisting of a pilot study to reinforce the antenatal screening and PMTCT capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT. This pilot study will be conducted in 9 selected maternities.

  2. an "evaluation" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.

Intervention component :
The TRI-MOM strategy includes 4 main activities:
  1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)

  2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests

  3. Assessment and treatment of women positive for any of the 3 targeted infections

  4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections

Evaluation component :
The TRI-MOM program will include three studies :
  1. A quantitative and qualitative cross-sectional study before and after the implementation of the strategy.

  2. A cohort study of pregnant women positive for any of the three infections.

  3. Cost and cost-effectiveness analysis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2800 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Integrated Antenatal Screening for HIV, Syphilis, and Hepatitis B Virus (HBV) in Pregnant Women in Burkina Faso and The Gambia
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
May 1, 2025
Anticipated Study Completion Date :
May 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: TRI-MOM

Women attending their first postnatal visit in one of the selected maternities (no maternal age limit) will be eligible to participate in the study

Other: TRI-MOM intervention
The TRI-MOM strategy includes 4 main activities: Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services) Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests Assessment and treatment of women positive for any of the 3 targeted infections Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections

Outcome Measures

Primary Outcome Measures

  1. Coverage of the strategy in the study maternities before its implementation [Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)]

    Proportion of women screened for HIV, Syphilis and HBV during pregnancy

  2. Coverage of the strategy in the study maternities after its implementation [Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)]

    Proportion of women screened for HIV, Syphilis and HBV during pregnancy

Secondary Outcome Measures

  1. Knowledge of the targeted infections before the strategy implementation [Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)]

    Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT

  2. Knowledge of the targeted infections after the strategy implementation [Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)]

    Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT

  3. Acceptability of the implemented strategy and PMTCT and preferences : screening refusal before the strategy implementation [Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)]

    Proportion of pregnant women who refuse the screening for any of the 3 targeted infections

  4. Acceptability of the implemented strategy and PMTCT and preferences : screening refusal after the strategy implementation [Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)]

    Proportion of pregnant women who refuse the screening for any of the 3 targeted infections

  5. Acceptability of the implemented strategy and PMTCT and preferences : treatment refusal before the strategy implementation [Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)]

    Proportion of positive pregnant women refusing treatment

  6. Acceptability of the implemented strategy and PMTCT and preferences : treatment refusal after the strategy implementation [Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)]

    Proportion of positive pregnant women refusing treatment

  7. Sensitivity of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) (PROTECT-B ancillary study) [Data collected at cohort inclusion]

    Percentage of HBsAg-positive women with a high viral load (≥200,000 IU/mL) who are positive for HBcrAg-RDT

  8. Specificity of the HBcrAg-RDT (PROTECT-B ancillary study) [Data collected at cohort inclusion]

    Percentage of HBsAg-positive women with a low viral load <200,000 IU/mL who are negative for HBcrAg-RDT

  9. Positive predictive value of the HBcrAg-RDT (PROTECT-B ancillary study) [Data collected at cohort inclusion]

    Proportion of subjects with a positive HBcrAg test result who truly have a high viral load (≥200,000 IU/mL)

  10. Negative predictive value of the HBcrAg-RDT (PROTECT-B ancillary study) [Data collected at cohort inclusion]

    Proportion of subjects with a negative HBcrAg test result who truly do not have a high viral load (≥200,000 IU/mL)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women attending a postnatal visit in one of the selected maternities (no maternal age limit)
Exclusion Criteria:
  • Refusal to participate in the study

  • Unable to provide consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Institut de Recherche pour le Developpement
  • Centre Muraz
  • Medical Research Council
  • Institut Pasteur
  • REVS PLUS Burkina Faso
  • Young Gambian Mums Fund
  • National AIDS Control Program Gambia

Investigators

  • Principal Investigator: Sylvie Boyer, PhD, UMR 1252 SESSTIM

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut de Recherche pour le Developpement
ClinicalTrials.gov Identifier:
NCT05951751
Other Study ID Numbers:
    First Posted:
    Jul 19, 2023
    Last Update Posted:
    Jul 19, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Institut de Recherche pour le Developpement
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2023